Janux Therapeutics, Inc.
JANX
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigenā¦ read more
Healthcare
Biotechnology
3 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$25.11
Price+0.56%
$0.14
1Y
Price
Market Cap
$1.509b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-1567.8%
EBITDA Margin-1178.9%
Net Profit Margin-1200.8%
Free Cash Flow MarginRevenue
$9.336m
-9.8%
1y CAGR+40.3%
3y CAGR+30.2%
5y CAGREarnings
-$77.742m
+4.6%
1y CAGR-23.1%
3y CAGR-147.2%
5y CAGREPS
-$1.36
+7.6%
1y CAGR-19.7%
3y CAGR-141.7%
5y CAGRBook Value
$1.012b
$1.051b
Assets$38.303m
Liabilities$22.612m
DebtDebt to Assets
2.2%
-0.3x
Debt to EBITDAFree Cash Flow
-$46.534m
-1.6%
1y CAGR-58.4%
3y CAGR-124.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company